This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Poseida Therapeutics’s 8K filing here.
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
See Also
- Five stocks we like better than Poseida Therapeutics
- Insider Trading – What You Need to Know
- MicroStrategy Stock Could Gain 50%, But Be Ready for Volatility
- Energy and Oil Stocks Explained
- 3 Key Analyst Upgrades: Why These Stocks Are Getting a Boost
- What is an Earnings Surprise?
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
